TRIB1 rs17321515 gene polymorphism increases the risk of coronary heart disease in general population and non-alcoholic fatty liver disease patients in Chinese Han population

Qun Liu1,4†, Shou-Sheng Liu3,5†, Zhen-Zhen Zhao3,5, Ben-Tian Zhao2, Shui-Xian Du2, Wen-Wen Jin2 and Yong-Ning Xin1,2,4,5*

Abstract

Background: Present evidences suggested that TRIB1 rs17321515 polymorphism was tightly associated with the increased risk of NAFLD and CHD. CHD is one of the main complications of NAFLD, whether TRIB1 rs17321515 polymorphism could affect the risk of CHD in general population and NAFLD patients in Chinese Han population was remain unknown. The present study was designed to investigate the association between TRIB1 rs17321515 polymorphism and the risk of CHD in general population and NAFLD patients in Chinese Han population, and investigate the effect of TRIB1 rs17321515 polymorphism on serum lipid levels.

Patients and methods: TRIB1 rs17321515 gene polymorphism was genotyped using the polymerase chain reaction (PCR) in healthy controls (n = 175), CHD patients (n = 155), NAFLD patients (n = 146), and NAFLD+CHD patients (n = 156). Serum lipid profiles were determined using biochemical methods. Statistical analyses were performed using SPSS 24.0 statistical software.

Results: The TRIB1 rs17321515 AA+GA genotypes were the significant risk factors for the CHD in general population (OR = 1.788; 95% CI: 1.104–2.897; P = 0.018) and in the NAFLD patients (OR = 1.760; 95% CI: 1.071–2.891; P = 0.026). After adjusted for age, gender, and body mass index, the risk for CHD in general population (OR = 1.857; 95% CI: 1.116–3.089; P = 0.017) and NAFLD patients was still significant (OR = 1.723; 95% CI: 1.033–2.873; P = 0.037). In addition, TRIB1 rs17321515 A carriers possess the higher lipid profiles in the included subjects.

Conclusions: TRIB1 rs17321515 AA+GA genotypes were significant associated with the risk of CHD in general population and in NAFLD patients in Chinese Han population. The rs17321515 A allele increases the serum lipid profiles in included subjects.

Keywords: Non-alcoholic fatty liver disease, TRIB1, Coronary heart disease, Polymorphism, Lipids metabolism
Background

Non-alcoholic fatty liver disease (NAFLD) is defined histologically as when more than 5% of liver cells are found to be suffering from steatosis, which is the manifestation of metabolic syndrome in liver [1]. The disease spectrum of NAFLD includes non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), fibrosis, liver cirrhosis and even hepatocellular carcinoma [2]. NAFLD has exceeded viral hepatitis and become the most prevalent liver disease in the world, and become the second largest cause of liver transplantation and the third largest cause of liver cancer [3]. Coronary heart disease (CHD) is a form of the metabolic syndrome, more and more epidemiology and clinical studies had been conducted to investigate the tightly association of NAFLD and CHD [4]. Increased evidences suggested that NAFLD is not only a marker of CHD and other structural, functional and arrhythmia complications, but also takes effects in the development and progression of these cardiac complications [5, 6]. Therefore, patients with NAFLD will benefited from the more rigorous monitoring and early treatment interventions to reduce the risk of CHD and other cardiac and arrhythmia complications.

NAFLD and CHD possess several the same influence factors such as lipids metabolism disorder, obesity and insulin resistance [7]. In addition, genetic factor such as gene polymorphism was also the significant risk factor for the NAFLD and CHD [8–11]. Genome-wide association study (GWAS) revealed many gene polymorphisms such as PNPLA3 rs738409 and TM6SF2 rs58542926 which were the significant risk factors for NAFLD [12, 13]. Abundant studies revealed that gene polymorphisms such as CD36 rs1761667, CDKN2BAS rs496892, and COX2 -765G > C were tightly associated with the risk of CHD in different countries [14–16]. Tribbles 1 (TRIB1) encoding Tribbles protein homolog 1 [17], proteins from the tribbles family include a MEK1-binding domain, an E3 ubiquitin ligase (COP1)-binding domain, and a pseudokinase domain, all of which are significant by interacting with respective partners [18]. GWAS in American identified that lots of novel genomic loci participated in the regulation of plasma triglyceride (TG) levels. One of those loci was the 8q24 locus, with the lead single nucleotide polymorphism (SNP) involving a linkage-disequilibrium block that contains the gene TRIB1 [19]. Although TRIB1 undergoes miRNA regulation, it is quite conserved in parts, containing a long 1.5 Kbp 3′ untranslated region (UTR) [20]. Under normal physiological conditions, TRIB1 can negatively regulate carbohydrate-responsive element-binding protein (ChREBP) via proteasome proteolysis ubiquitination, raising the microsomal triglyceride transfer protein (MTTP) to terminate lipogenesis. In the absence of TRIB1, the process of lipogenesis is aberrant and the serum lipid disorders was occurred [21]. GWAS studies have repeatedly confirmed that TRIB1 gene polymorphisms were associated with dyslipidemia [22–25], and several studies had shown that TRIB1 gene variants can increase the risk of CHD [26, 27]. In addition, previous studies have confirmed that TRIB1 gene variation can also increase the risk of NAFLD [28–30].

In consideration of the prevalent complication of NAFLD and CHD, understanding of effect of genetic factors on the patients with NAFLD and CHD were

![Fig. 1 The flow chart of this study](chart.png)
The aim of this study was to investigate the association of TRIB1 rs17321515 gene polymorphism with the risk of CHD in NAFLD patients in Chinese Han population, and investigate the effect of TRIB1 rs17321515 on the serum lipid profiles of patients with NAFLD and CHD.

Patients and methods

Study subjects

This study was approved by the Ethical Committee of Qingdao Municipal Hospital (Qingdao, China), and this study was conducted in accordance with the principles of the Helsinki declaration and its appendices [31]. All the subjects had signed the informed consent before participating in this study.

From June 2018 to November 2018, 146 NAFLD patients (65 females and 81 males, median age 64.00 years) diagnosed by B-type ultrasonography, 155 CHD patients (72 females and 83 males, median age 60.00 years) diagnosed by coronary angiography, 156 patients (80 females and 76 males, median 64.00 years) with both NAFLD and CHD diagnosed by B-type ultrasonography and coronary angiography, and 175 healthy controls (87 females and 88 males, median 62.00 years) that matched for sex and age were enrolled in this study. Clinical data of all the subjects were collected from the department of Gastroenterology.

### Table 1: Clinical Characteristics of CHD Patients and Healthy controls

| Parameters          | CHD (n = 155) | Controls (n = 175) | Statistics | P value |
|---------------------|---------------|-------------------|------------|---------|
| Male/Female         | 83/72         | 88/87             | \(\chi^2 = 0.350\) | 0.554   |
| Age, y              | 60.00 (59.00, 75.00) | 62.00 (53.00, 68.00) | \(Z = −1.013\) | 0.311   |
| BMI, kg/m\(^2\)     | 24.20 ± 2.73  | 22.44 ± 2.88      | \(t = 5.632\) | < 0.001 |
| ALT, U/L            | 19.21 (14.57, 33.40) | 17.96 (12.57, 24.20) | \(Z = −2.239\) | 0.025   |
| AST, U/L            | 22.45 (16.70, 37.78) | 20.78 (17.60, 24.35) | \(Z = −1.924\) | 0.054   |
| GGT, U/L            | 23.75 (17.09, 36.74) | 19.91 (15.24, 29.92) | \(Z = −2.117\) | 0.034   |
| ALP, U/L            | 83.84 (66.72, 109.08) | 69.71 (57.27, 83.63) | \(Z = −1.083\) | 0.279   |
| TG, mmol/L          | 1.23 (0.90, 1.61) | 1.12 (0.86, 1.62) | \(Z = −3.026\) | 0.002   |
| TC, mmol/L          | 4.19 (3.71, 5.13) | 4.64 (3.66, 5.18) | \(Z = −1.015\) | 0.311   |
| HDL, mmol/L         | 1.00 (0.85, 1.20) | 1.31 (1.05, 1.47) | \(Z = −7.493\) | < 0.001 |
| LDL, mmol/L         | 2.49 (2.06, 3.18) | 3.01 (2.61, 3.56) | \(Z = −3.552\) | < 0.001 |
| TBIL, μmol/L        | 13.50 (10.60, 17.96) | 12.10 (9.50, 15.10) | \(Z = −0.366\) | 0.714   |
| FPG, mmol/L         | 5.02 (4.49, 6.02) | 4.54 (4.06, 5.05) | \(Z = −5.879\) | < 0.001 |

**Abbreviations**: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FPG, fasting plasma glucose; GGT, \(\gamma\)-glutamyltransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TBIL, total bilirubin; TC, total cholesterol; TG, triglyceride

### Table 2: Clinical Characteristics of NAFLD+CHD Patients and NAFLD Patients

| Parameters          | NAFLD+CHD (n = 156) | NAFLD (n = 146) | Statistics | P value |
|---------------------|---------------------|-----------------|------------|---------|
| Male/Female         | 76/80               | 81/65           | \(\chi^2 = 0.421\) | 0.516   |
| Age, y              | 64.00 (59.00, 72.75) | 64.00 (50.00, 74.00) | \(Z = −0.644\) | 0.520   |
| BMI, kg/m\(^2\)     | 25.47 (23.05, 27.68) | 26.35 (24.86, 28.49) | \(Z = −3.431\) | 0.001   |
| ALT, U/L            | 23.58 (16.07, 34.36) | 22.67 (18.30, 35.68) | \(Z = −0.919\) | 0.358   |
| AST, U/L            | 21.29 (16.80, 32.02) | 21.55 (18.38, 28.09) | \(Z = −0.647\) | 0.517   |
| GGT, U/L            | 30.70 (21.31, 42.67) | 32.55 (20.97, 47.79) | \(Z = −0.986\) | 0.324   |
| ALP, U/L            | 79.52 (66.58, 96.46) | 68.48 (59.09, 81.81) | \(Z = −3.124\) | 0.002   |
| TG, mmol/L          | 1.58 (1.13, 2.18)   | 1.54 (1.16, 2.21) | \(Z = −0.145\) | 0.885   |
| TC, mmol/L          | 4.64 (3.75, 5.54)   | 5.42 (4.98, 6.02) | \(Z = −1.682\) | 0.093   |
| HDL, mmol/L         | 1.02 (0.88, 1.12)   | 1.19 (1.05, 1.32) | \(Z = −0.674\) | < 0.001 |
| LDL, mmol/L         | 2.86 (2.10, 3.45)   | 3.30 (2.97, 3.52) | \(Z = −1.332\) | 0.183   |
| TBIL, μmol/L        | 12.70 (9.70, 16.77) | 12.00 (10.00, 14.90) | \(Z = 0.084\) | 0.940   |
| FPG, mmol/L         | 5.70 (4.68, 6.96)   | 4.96 (4.52, 5.79) | \(Z = −3.503\) | < 0.001 |

**Abbreviations**: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FPG, fasting plasma glucose; GGT, \(\gamma\)-glutamyltransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TBIL, total bilirubin; TC, total cholesterol; TG, triglyceride
and Cardiology, and the Medical center of Qingdao Municipal Hospital. All the individuals were unrelated Northern Han Chinese origin. NAFLD was diagnosed by a standard clinical evaluation, according to the criteria of the American association for the study of liver diseases (AASLD) [32]. CHD was diagnosed by a percutaneous coronary angiography, with the presence of at least 50% stenosis in at least one of the coronary arteries. Subjects who had other liver diseases, other cardiac disorders or diabetes mellitus were excluded.

Biochemical analyses
The basic clinical information (name, gender, age, body height, and weight) were obtained by a standard study questionnaire. The body mass index (BMI) was calculated using the equation that mass (kg)/height (m)². After a 12-h overnight fasting, blood sample was collected from median vein of each subject, and the blood sample was placed into an ethylene diamine tetraacetic acid (EDTA)-containing tube. The serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), total bilirubin (TBIL), fasting plasma glucose (FPG) were measured by standard clinical laboratory techniques (IChem-540 automatic biochemical analyzer, Shenzhen, China), respectively. Environmental factors were excluded in the study.

Genomic DNA extraction and genotyping
Blood genomic DNA was isolated with a genomic DNA purification kit (TIANGEN, Beijing, China) according to the manufacturer’s instructions and stored at −20 °C until use. The genotyping of TRIB1 rs17321515 was conducted using the polymerase chain reaction (PCR). Primers for PCR were 5′-ACGTTGGATGAGATTCCCCCTTT TTAG-3′ and 5′-ACGTTGGATGGAAACAAGGACCTT CTCGTCCTC-3′. PCR amplification was performed under the following conditions: an initial denaturation at 94 °C for 5 min, followed by 45 cycles of denaturing at 94 °C for 20 s, annealing at 56 °C for 30 s, and extending at 72 °C for 1 min. The genotypes of rs17321515 were detected by direct DNA sequencing using the ABI veriti-384 Prism sequence detection system, and the raw data were analyzed using MassARRAY TYPER4.0 software (Agena, Inc). Genotyping was performed in blinded fashion and the success rates were > 95%.

Statistical analysis
Statistical analysis was performed using the statistical package for the social sciences (SPSS) version 24.0 (SPSS Inc. Chicago, IL, USA). The Hardy-Weinberg equilibrium of expected and observed genotype distribution was analyzed by Pearson’s χ² test. After testing for normality, continuous variables were shown as the mean ± standard deviation or median (interquartile range) for normal and abnormal distributed parameters, respectively. The t-test and Wilcoxon rank sum test were used for comparison of continuous data between groups. The Genotypes and allele frequencies were evaluated using the χ² test. The association between SNP and CHD risk in NAFLD patients was estimated by computing odds ratios (ORs) and 95% confidence intervals (CI) from the binary logistic regression analyses. P < 0.05 was considered as statistically significant.

Results
Clinical characteristics of the study participants
The flow chart of this study was shown in the Fig. 1. The clinical characteristics of CHD patients and healthy controls are shown in the Table 1. The two groups were matched for gender and age (all P > 0.05). The CHD patients had higher BMI value and serum levels of ALT, GGT, TG and FPG than healthy controls (all P < 0.05), besides, the serum level of HDL and LDL in CHD patients was significant lower compared to the healthy controls (all P < 0.05). The clinical characteristics of NAFLD+CHD patients and

| Table 3 | Results of the Hardy-Weinberg Equilibrium |
|---------|------------------------------------------|
|         | χ² | P value |
| Control | 1.693 | 0.193 |
| CHD     | 0.091 | 0.762 |
| NAFLD+CHD | 0.003 | 0.957 |
| NAFLD   | 0.403 | 0.526 |

| Table 4 | Distributions of the TRIB1 rs17321515 Genotypes and Alleles in the Study Groups |
|---------|---------------------------------|
|         | NAFLD | CHD     | NAFLD+CHD | Control |
| Genotypes |       |        |           |         |
| GG       | 37 (26.6) | 39 (22.8) | 60 (39.0) | 67 (40.6) |
| AG       | 73 (52.5) | 72 (42.1) | 72 (46.8) | 70 (42.4) |
| AA       | 29 (20.9) | 30 (35.1) | 22 (14.3) | 28 (17.0) |
| Alleles  |       |        |           |         |
| G        | 147 (52.9) | 150 (53.2) | 192 (62.3) | 204 (61.8) |
| A        | 131 (47.1) | 132 (46.8) | 116 (37.7) | 126 (38.2) |

P 1: CHD vs Control; P 2: NAFLD+CHD vs NAFLD
NAFLD+CHD patients had higher serum levels of ALP, TBIL, FPG than NAFLD patients (all \( P < 0.05 \)), lower BMI and HDL than NAFLD patients (all \( P < 0.05 \)).

### Genotype and allele distributions of TRIB1 rs17321515

The genotype distributions of \( \text{TRIB1} \) rs17321515 in the four groups were in accordance with the Hardy-Weinberg equilibrium (all \( P > 0.05 \)) (Table 3). As described in the Table 4, there was significant difference in the allele distribution of \( \text{TRIB1} \) rs17321515 between CHD patients and controls group (\( P = 0.031 \)). The \( \text{TRIB1} \) rs17321515 GA + AA genotypes were the significant risk factor for the development of CHD (OR = 1.788; 95% CI: 1.104–2.897; \( P = 0.018 \)), after adjusted for age, gender, and body mass index, the risk of \( \text{TRIB1} \) rs17321515 GA + AA genotypes were still marked (OR = 1.760; 95% CI: 1.071–2.891; \( P = 0.026 \)) (Table 5). In addition, there was significant difference in the allele distribution of \( \text{TRIB1} \) rs17321515 between NAFLD+CHD patients and NAFLD group (\( P = 0.021 \)) (Table 4). The \( \text{TRIB1} \) rs17321515 GA + AA genotypes were the significant risk factor for the development of CHD in NAFLD patients (OR = 1.760; 95% CI: 1.071–2.891; \( P = 0.026 \)), after adjusted for age, gender, and body mass index, the risk of \( \text{TRIB1} \) rs17321515 GA + AA genotypes were still marked (OR = 1.723; 95% CI: 1.033–2.873; \( P = 0.037 \)) (Table 5).

Association of the TRIB1 rs17321515 gene polymorphism with clinical parameters characteristics in each group subjects

We compared the \( \text{TRIB1} \) rs17321515 A allele with the clinical characteristics of the four groups to estimate whether the rs17321515 A allele was correlated with clinical parameters. As the results shown in the Table 6, there was no significant difference between the A allele carriers and non-carriers in the overall series and in the NAFLD patients (all \( P > 0.05 \)) (Tables 6 and 7). Higher serum level of FPG in the A allele carriers was observed compared to the non-carriers in the CHD group (\( P = 0.021 \)) (Table 8). In the NAFLD+CHD patients, the A allele carriers had the higher serum HDL level than non-carriers (\( P = 0.015 \)) (Table 9). In the healthy controls, the A allele carriers had the higher serum TC level than non-carriers (\( P = 0.001 \)) (Table 10).

**Table 5** Odds Ratios According to Genotypes of TRIB1 rs17321515 Gene Polymorphism in Study Group

|                   | Unadjusted | Adjusted* |
|-------------------|------------|-----------|
|                   | OR (95% CI)| OR (95% CI)| OR (95% CI)| OR (95% CI)| OR (95% CI)| OR (95% CI)|
|                   |            | P1        |            | P2        |            | P1        |            |
| GG                | 1.788 (1.104–2.897) | 0.018 | 1.760 (1.071–2.891) | 0.026 | 1.857 (1.116–3.089) | 0.017 | 1.723 (1.033–2.873) | 0.037 |
| GA + AA           |            |          |            |          |            |          |            |

* Binary logistic regression model was adjusted for age, gender, and body mass index.

\( P_1 \): CHD vs Control; \( P_2 \): NAFLD+CHD vs NAFLD

**Table 6** Clinical Characteristics of TRIB1 rs17321515 A allele Carriers and Non-carriers in the Overall Series

| Parameters          | Carriers (n = 396) | Non-carriers (n = 203) | Statistics | \( P \) value |
|---------------------|-------------------|------------------------|------------|--------------|
| Male/Female         | 206/190           | 104/99                 | \( \chi^2 = 0.033 \) | 0.855        |
| Age, y              | 64.00 (54.25, 72.00) | 65.00 (54.00, 74.00) | \( Z = -1.221 \) | 0.222        |
| BMI, kg/m²          | 24.66 (22.51, 26.83) | 24.73 (22.39, 26.47) | \( Z = -0.563 \) | 0.573        |
| ALT, U/L            | 21.31 (15.50, 32.31) | 20.88 (14.42, 29.42) | \( Z = -1.275 \) | 0.202        |
| AST, U/L            | 21.32 (17.63, 29.36) | 21.13 (17.15, 26.80) | \( Z = -0.804 \) | 0.422        |
| GGT, U/L            | 26.64 (18.73, 40.29) | 25.32 (16.85, 39.86) | \( Z = -1.577 \) | 0.115        |
| ALP, U/L            | 75.65 (62.23, 91.77) | 73.06 (59.43, 87.69) | \( Z = -1.691 \) | 0.091        |
| TG, mmol/L          | 1.41 (0.98, 1.96) | 1.31 (0.97, 1.83) | \( Z = -1.427 \) | 0.153        |
| TC, mmol/L          | 4.72 (3.89, 5.54) | 4.86 (4.03, 5.41) | \( Z = -0.603 \) | 0.546        |
| HDL, mmol/L         | 1.10 (0.95, 1.31) | 1.08 (0.93, 1.32) | \( Z = -0.577 \) | 0.564        |
| LDL, mmol/L         | 3.00 (2.36, 3.47) | 2.99 (2.48, 3.44) | \( Z = -0.207 \) | 0.836        |
| TBIL, umol/L        | 12.70 (9.80, 16.27) | 13.20 (10.00, 17.00) | \( Z = -0.692 \) | 0.489        |
| FPG, mmol/L         | 4.95 (4.41, 5.77) | 4.96 (4.41, 6.11) | \( Z = -0.730 \) | 0.466        |

Discussion

NAFLD has become a worldwide public health problem. Clinical experience and epidemiological evidences showed
that NAFLD-related mortality not only referred to the liver itself, but also accompanied with the complication such as the increased risk of CHD [33, 34]. NAFLD could aggravate insulin resistance in the body and liver that cause atherosclerotic dyslipidemia, and release a variety of pro-inflammatory, pro-coagulant, and pro-fibrotic mediators, which may play an important role in the pathophysiology of cardiac and arrhythmia complications [33, 35]. Single nucleotide polymorphism (SNP) as a significant genetic factor, plays an important role in the development of NAFLD and CHD [36, 37]. Multiple studies have confirmed that TRIB1 gene polymorphisms can increase the risk of NAFLD and the risk of CHD [28, 29, 38]. In this study, we investigated the relationship of TRIB1 rs17321515 gene polymorphism with the risk of CHD, and the risk of CHD in NAFLD patients in Chinese Han population for the first time. The results showed that TRIB1 rs17321515 GA + AA genotypes were significantly associated with the increased risk of CHD in healthy controls and NAFLD patients.

Tribbles-1 (TRIB1) is one of the members of tribbles family which were first identified in Drosophila and possess the function to regulate the cell division and migration [39]. Previous studies confirmed that TRIB1 encodes a human homologue of the Drosophila tribbles protein, and the relationship of TRIB1 variant with the serum lipids metabolism was discovered by GWAS in the European population [40, 41]. To further explore the role of TRIB1 in lipoprotein metabolism, Burkhardt et al. found the serum levels of TG and

### Table 7 Clinical Characteristics of TRIB1 rs17321515 A allele Carriers and Non-carriers in the NAFLD Patients

| Parameters | Carriers (n = 102) | Non-carriers (n = 37) | Statistics | P value |
|------------|-------------------|----------------------|------------|--------|
| Male/Female | 54/48             | 20/17                | χ² = 0.014 | 0.907  |
| Age, y     | 64.00 (45.00, 74.00) | 67.00 (45.00, 75.50) | Z = -0.851 | 0.395  |
| BMI, kg/m² | 26.47 (24.87, 28.74) | 26.23 (24.62, 28.06) | Z = -0.110 | 0.913  |
| ALT, U/L   | 22.84 (18.27, 36.72) | 22.34 (17.79, 36.40) | Z = -0.434 | 0.665  |
| AST, U/L   | 21.55 (18.84, 28.10) | 21.55 (17.33, 27.56) | Z = -0.591 | 0.555  |
| GGT, U/L   | 33.15 (22.38, 47.95) | 29.14 (18.47, 47.54) | Z = -1.075 | 0.285  |
| ALP, U/L   | 71.83 ± 15.31      | 68.47 ± 19.99        | t = 0.104  | 0.296  |
| TG, mmol/L | 1.73 (1.16, 2.26)   | 1.44 (1.17, 2.17)    | Z = -0.624 | 0.532  |
| TC, mmol/L | 5.42 ± 0.80        | 5.53 ± 0.87          | t = -0.688 | 0.493  |
| HDL, mmol/L| 1.18 (1.05, 1.29)   | 1.21 (1.02, 1.35)    | Z = -0.331 | 0.740  |
| LDL, mmol/L| 3.30 (2.95, 3.50)   | 3.40 (3.17, 3.67)    | Z = -1.833 | 0.067  |
| TBIL, umol/L| 11.90 (9.80, 14.62) | 13.90 (10.10, 17.90) | Z = -1.258 | 0.208  |
| FPG, mmol/L| 4.94 (4.50, 5.80)   | 4.96 (4.61, 5.96)    | Z = -0.060 | 0.952  |

### Table 8 Clinical Characteristics of TRIB1 rs17321515 A allele Carriers and Non-carriers in the CHD Patients

| Parameters | Carriers (n = 102) | Non-carriers (n = 39) | Statistics | P value |
|------------|-------------------|----------------------|------------|--------|
| Male/Female | 50/52             | 20/19                | χ² = 0.058 | 0.810  |
| Age, y     | 66.12 ± 9.96      | 68.10 ± 12.61        | t = -0.883 | 0.381  |
| BMI, kg/m² | 24.22 (22.76, 25.71) | 24.51 (22.50, 26.26) | Z = -0.199 | 0.843  |
| ALT, U/L   | 18.88 (14.74, 33.03) | 20.27 (12.81, 43.41) | Z = -0.018 | 0.985  |
| AST, U/L   | 22.13 (16.22, 36.05) | 22.73 (16.89, 43.23) | Z = -0.249 | 0.803  |
| GGT, U/L   | 23.64 (17.30, 36.65) | 25.98 (16.89, 46.81) | Z = -0.350 | 0.726  |
| ALP, U/L   | 84.87 (67.18, 110.11) | 74.64 (62.40, 108.33) | Z = -0.843 | 0.399  |
| TG, mmol/L | 1.21 (0.90, 1.69)  | 1.27 (0.92, 1.59)    | Z = -0.549 | 0.583  |
| TC, mmol/L | 4.15 (3.59, 5.11)  | 4.07 (3.68, 5.13)    | Z = -0.108 | 0.914  |
| HDL, mmol/L| 0.98 (0.85, 1.16)  | 1.01 (0.82, 1.25)    | Z = 0.004  | 0.366  |
| LDL, mmol/L| 2.49 (2.02, 3.23)  | 2.30 (2.08, 3.17)    | Z = -0.452 | 0.651  |
| TBIL, umol/L| 13.30 (10.67, 17.92) | 15.40 (10.60, 18.69) | Z = -0.092 | 0.924  |
| FPG, mmol/L| 5.31 (4.82, 6.43)  | 4.89 (4.37, 5.55)    | Z = -2.307 | 0.021  |
cholesterol were inversely associated with the expression of hepatic TRIB1 in mice [17]. Several studies had reported the effect of TRIB1 rs17321515 on the serum lipids metabolism. In a Chinese Han cohort study, TRIB1 rs17321515 AA genotype carriers had higher TG level than GG genotype carriers [42]. Katalin et al. also found that TRIB1 rs17321515 AA genotype carriers had higher serum TG and TC levels than GG + GA genotypes carriers [43]. In consideration of the higher mortality rate of NAFLD-related CHD than the single liver disease, it is meaningful to investigate the effect of TRIB1 rs17321515 gene polymorphism on the risk of CHD in general population and NAFLD patients, and the effect on the serum lipids levels [4, 44]. In this study, we observed that TRIB1 rs17321515 AA+GA genotypes were significantly associated with the risk of CHD in general Chinese Han population. Besides, TRIB1 rs17321515 AA+GA genotypes carriers in NAFLD patients had a higher CHD risk than GG genotype carriers. Our results showed that TRIB1 rs17321515 polymorphism was a significant risk factor for CHD in the general population and could increase the CHD risk in NAFLD patients in Chinese Han population. Moreover, TRIB1 rs17321515 A allele could affect the serum lipids levels such as FPG, HDL, and TC in each group. Our conclusion is consistent with the previous studies which were conducted in other countries [26, 43, 45].

Some limitations of our study must be acknowledged. Firstly, all the included subjects in this study are Chinese Han nationality, our conclusion may not be applicable to other nationality absolutely. Secondly, lacking of liver biopsy is the main limitation of our study, however, liver biopsy is invasive, and may lead to a small probability of bias.

### Table 9 Clinical Characteristics of TRIB1 rs17321515 A allele Carriers and Non-carriers in the NAFLD+CHD Patients

| Parameters   | Carriers (n = 94) | Non-carriers (n = 60) | Statistics | P value |
|--------------|------------------|----------------------|------------|---------|
| Male/Female  | 50/44            | 30/30                | χ² = 0.149 | 0.699   |
| Age, y       | 63.34 ± 10.53    | 66.58 ± 10.92        | t = -1.837 | 0.068   |
| BMI, kg/m²   | 25.54 ± 3.24     | 25.35 ± 3.21         | t = 0.344  | 0.731   |
| ALT, U/L     | 23.72 (17.16, 37.60) | 23.30 (14.58, 32.86) | Z = -1.106 | 0.269   |
| AST, U/L     | 21.72 (17.37, 32.15) | 20.12 (15.67, 32.54) | Z = -0.728 | 0.467   |
| GGT, U/L     | 32.39 (22.76, 44.39) | 29.28 (19.67, 40.77) | Z = -1.384 | 0.166   |
| ALP, U/L     | 80.61 (65.89, 98.21) | 76.27 (62.27, 89.86) | Z = -0.947 | 0.344   |
| TG, mmol/L   | 1.70 (1.31, 2.21) | 1.40 (1.00, 2.09)    | Z = -1.932 | 0.053   |
| TC, mmol/L   | 4.66 (3.73, 5.67) | 4.54 (3.75, 5.34)    | Z = -0.943 | 0.346   |
| HDL, mmol/L  | 1.04 (0.92, 1.17) | 0.95 (0.82, 1.08)    | Z = -2.435 | 0.015   |
| LDL, mmol/L  | 2.80 (2.08, 3.46) | 2.88 (2.03, 3.33)    | Z = -0.369 | 0.712   |
| TBL, umol/L  | 13.30 (9.70, 17.07) | 12.48 (9.42, 16.48) | Z = -0.513 | 0.608   |
| FPG, mmol/L  | 5.64 (4.65, 7.16) | 5.79 (4.67, 6.87)    | Z = -0.371 | 0.711   |

### Table 10 Clinical Characteristics of TRIB1 rs17321515 A allele Carriers and Non-carriers in the Healthy Controls

| Parameters   | Carriers (n = 98) | Non-carriers (n = 67) | Statistics | P value |
|--------------|------------------|----------------------|------------|---------|
| Male/Female  | 52/46            | 34/33                | χ² = 0.085 | 0.770   |
| Age, y       | 62.00 (53.00, 69.00) | 63.00 (52.00, 68.00) | Z = -0.349 | 0.727   |
| BMI, kg/m²   | 22.27 ± 2.81     | 22.66 ± 3.02         | t = -0.850 | 0.397   |
| ALT, U/L     | 17.93 (12.50, 25.86) | 19.70 (12.57, 23.82) | Z = -0.041 | 0.967   |
| AST, U/L     | 19.94 (12.28, 25.69) | 20.87 (18.10, 23.01) | Z = -0.075 | 0.940   |
| GGT, U/L     | 20.05 (15.15, 30.21) | 19.59 (15.59, 31.89) | Z = -0.071 | 0.943   |
| ALP, U/L     | 69.92 (57.31, 82.96) | 66.73 (54.60, 83.63) | Z = -0.493 | 0.622   |
| TG, mmol/L   | 1.13 (0.86, 1.65) | 1.08 (0.88, 1.67)    | Z = -0.017 | 0.987   |
| TC, mmol/L   | 4.85 (4.30, 5.32) | 4.24 (3.44, 5.00)    | Z = -3.263 | 0.001   |
| HDL, mmol/L  | 1.35 (1.06, 1.51) | 1.28 (1.03, 1.40)    | Z = -1.175 | 0.240   |
| LDL, mmol/L  | 3.11 ± 0.77      | 3.09 ± 0.59          | t = 0.173  | 0.863   |
| TBL, umol/L  | 11.55 (9.37, 15.22) | 12.30 (9.50, 15.10) | Z = -0.484 | 0.628   |
| FPG, mmol/L  | 4.56 (4.11, 5.05) | 4.50 (4.04, 4.97)    | Z = -0.616 | 0.538   |
serious morbidity. Thereby, we used abdominal ultrasound to diagnose NAFLD in the present study. Thirdly, some of our subjects were long-term users of lipid-lowering drugs, which will affect the accuracy of the results to some extent. Lastly, nutraceuticals can influence the lipid levels [46], but we did not consider this factor in this study.

Conclusion
In summary, we investigated the relationship of TRIB1 rs17321515 with the risk of CHD in general population and NAFLD patients in Chinese Han population for the first time. Our results showed that TRIB1 rs17321515 AA+GA genotypes are associated with an increased risk of CHD in general population and NAFLD patients, and the rs17321515 A allele affects the serum lipid levels of multiple lipid profiles in included subjects. Diverse ethnic groups and larger sample sizes are needed to investigate in further study to confirm the present data.

Abbreviations
AASLD: American association for the study of liver diseases; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; CHD: Coronary heart disease; ChREBP: Carbohydrate-responsive element-binding protein; CI: Confidence intervals; EDTA: Ethylene diamine tetracetic acid; FPG: Fasting plasma glucose; GGT: Gamma-glutamyltransferase; GWAS: Genome-wide association study; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; MTT: MTT-assay; MTTP: Microsomal triglyceride transfer protein; NAFL: Non-alcoholic fatty liver; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; ORs: Odds ratios; PCR: Polymerase chain reaction; SNP: Single nucleotide polymorphism; TBIL: Total bilirubin; TG: Triglycerides; TRIB1: Tribbles 1

Authors’ contributions
Study concept and design: LQ and XYN. Subjects collection: LQ, LSS, ZZZ. Drafting and writing of the manuscript: LQ and LSS. The revision of the manuscript: XYN. All authors approved the final manuscript.

Funding
This study was supported by Grants of National Natural Science Foundation of China (31770837) and the Qingdao People’s livelihood science and technology plan (18–1–6-68-nsh).

Availability of data and materials
None.

Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of Qingdao Municipal Hospital before participation (Approval NO.2017–20). All the subjects have signed written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1The Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao 266011, China. 2Department of Infectious Disease, The Affiliated Qingdao Municipal Hospital of Qingdao University, Jiaozhou Road, Qingdao 266011, Shandong Province, China. 3Central Laboratories, The Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao 266071, China. 4Department of Gastroenterology, The Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao 266011, China. 5Digestive Disease Key Laboratory of Qingdao, Qingdao 266071, China.

Received: 3 July 2019 Accepted: 15 August 2019
Published online: 31 August 2019

References
1. Cha JY, Kim DH, Chun KH. The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Lab Anim Res. 2018;34:133–9.
2. Kovalic A, Banerjee P, Tran QT, Singal AK, Satapathy SK. Genetic and epigenetic culprits in the pathogenesis of nonalcoholic fatty liver disease. J Clin Exp Hepatol. 2018;8:390–402.
3. Wong WW. Current prevention and treatment options for NAFLD. Adv Exp Med Biol. 2018;1061:149–57.
4. Li XL, Sui QJ, Lu LJ, Zhang NN, Xu X, Dong QY, Xin YN, et al. Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise review. Lipids Health Dis. 2016;15:53.
5. Tarantino G, Caputi A. JNKs, insulin resistance and inflammation: a possible link between NAFLD and coronary artery disease. World J Gastroenterol. 2011;17:3785–94.
6. Mantovani A, Ballestri S, Lonardo A, Targher G. Cardiovascular disease and myoccardial abnormalities in non-alcoholic fatty liver disease. Dig Dis Sci. 2016;61:246–67.
7. Wojcik-Chyž K, Koslinska-Berkan E, Plekarska A. The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases. Clin Exp Hepatol. 2018;8(1–6).
8. Severson Tl, Besur S, Bonkovsky HL. Genetic factors that affect nonalcoholic fatty liver disease: a systematic clinical review. World J Gastroenterol. 2016;22:6742–56.
9. Vassalle C, Andreassi MG. Genetic polymorphisms of the natriuretic peptide system in the pathogenesis of cardiovascular disease: what lies on the horizon? Clin Chem. 2009;55:878–87.
10. Mirrman P, Essandor Z, Hosseni-Esfahani F, Koochakpoor G, Daneshpour MS, Sedaghati-Khayat B, Atizi F. Genetic variations of cholesterol ester transfer protein gene and diet interactions in relation to lipid profiles and coronary heart disease: a systematic review. Nutr Metab (Lond). 2017;14:77.
11. Eslam M, Valenti L, Roméo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol. 2018;68:268–79.
12. Sookolain S, Pirola CJ. Genetic predisposition in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2017;23:1–12.
13. Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjaerg-Hansen A, Vogt TF, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46:352–6.
14. Momeni-Moghaddam MA, Asadikaram G, Akbari H, Abolhassani M, Masoomi N, Namidy Z, Khaksari M. CD36 gene polymorphism rs1761667 (G > a) is associated with hypertension and coronary artery disease in an Iranian population. BMC Cardiovasc Disord. 2019;19:140.
15. Mangalarapu M, Vinukonda S, Kamaravalli PL, Nagula P, Koduganti RR, Koripallly A, Sagurthi SR. Association of CDKN2BAS gene polymorphism with periodontitis and coronary artery disease from south Indian population. Gene. 2019;70:324–32.
16. Kim II, Kim SH, Cha DH, Lim SW, Moon JY, Kim JO, Ryu CS, et al. Association of CDX2 -765G>C promoter polymorphism and coronary artery disease in Korean population. Genes Genom. 2019;41:1055–62.
17. Burkhardt R, Toh SA, Lagor WR, Birkeband A, Levin M, Li X, Robblee M, et al. Triglycerides and myoccardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice. J Clin Invest. 2010;120:4410–4.
18. Makishima S, Boonvisut S, Ishizuka Y, Watanabe K, Nakayama K, Iwamoto S. The a>T polymorphism of the tribbles homolog 1 gene is associated with hepatic lipid metabolism in humans. Biochem Soc Trans. 2015;43:1079–84.
19. Bauerey R, Yenilmez BO, Rader DJ. Triglycerides-1: a novel regulator of hepatic lipid metabolism in humans. Biochem Soc Trans. 2015;43:1079–84.
20. Soubyreand S, Martinuk A, Lau P, McPherson R. TRIB1 is regulated post-transcriptionally by proteasomal and non-proteasomal pathways. PLoS One. 2016;11:e0152346.
21. Iwamoto S, Boonvisut S, Makishima S, Ishizuka Y, Watanabe K, Nakayama K. The role of TRIB1 in lipid metabolism, from genetics to pathways. Biochem Soc Trans. 2015;43:1063–8.
22. Ikeoka T, Hayashida N, Nakazato M, Sekita T, Murata-Mori F, Ando T, Abiru N, et al. The a>T polymorphism of the tribbles homolog 1 gene is associated with
with serum triglyceride concentrations in Japanese community-dwelling women. Tohoku J Exp Med. 2014;233:149–53.

23. Shen Y, Xi B, Zhao X, Cheng H, Hou D, Wu L, Wang X, et al. Common genetic variants associated with lipid profiles in a Chinese pediatric population. Hum Genet. 2013;132:1275–85.

24. Walia G, Gupta V, Aggarwal A, Asghar M, Duddbridge F, Timpson N, Singh NS, et al. Association of common genetic variants with lipid traits in the Indian population. PLoS One. 2014;9:e101688.

25. Varga TV, Sonestedt E, Shungin D, Koivula RW, Hallmans G, Escher SA, Barroso I, et al. Genetic determinants of long-term changes in blood lipid concentrations: 10-year follow-up of the GLACIER study. PLoS Genet. 2014;10:e1004398.

26. Dourmis, S, Aubrey, S, Naing, T, Martinuk, A, Nikpay, M, Williams, A, Buck, J, et al. Functional analysis of the TRIB1 associated locus linked to plasma triglycerides and coronary artery disease. J Am Heart Assoc. 2014;3:e000884.

27. Ghouj, N, Preiss, D, Sattar, N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology. 2010;52:1156–61.

28. Kitamoto A, Kitamoto T, Nakamura T, Ogawa Y, Yoneda M, Hiyogo H, Ochi H, et al. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endoc J. 2014;61:683–9.

29. Speliotes EK, Yerges-Armstrong LM, Wu J, Hmaniae R, Kim LJ, Palmer CD, Dudbridge F, et al. Genome-wide association analysis identifies variants associated with non-alcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7:e1001324.

30. Liu Q, Xue F, Meng J, Liu S, Chen L, Gao H, Geng N, et al. TRIB1 rs17321515 and rs2954029 gene polymorphisms increase the risk of non-alcoholic fatty liver disease in Chinese Han population. Lipids Health Dis. 2019;18:61.

31. Rickham PP. Human experimentation. Code of Ethics of the World Medical Association Declaration of Helsinki. Br Med J. 1964;2:177.

32. Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease update 2017. World J Gastroenterol. 2018;24:1096–100.

33. Scicchitano P, Cameli M, Maiello M, Maierl, Modesti PA, Muiesan ML, Novo S, Palmero P, et al. Nutaceuticals and dyslipidaemia: beyond the common therapeutics. J Funct Foods. 2014;6:11–22.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.